Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Inclusion Criteria: Males and females aged 18-35 years initially (subjects aged 8-17 may be included at a later stage, starting with age 12-17 years, followed by age 8-11 years). Body weight between 40-120 kg initially (subjects weighing 21-39 kg may be included at a later stage). Recent onset type 1 diabetes mellitus, diagnosed with 100 days of first dose. Peak stimulated C-peptide levels \>/= 0.2 pmol/L following mixed meal tolerance test Exclusion Criteria: Any form of diabetes other than auto-immune type 1 (eg, type 2 diabetes, maturity onset diabetes of the young, latent autoimmune diabetes of the adult). Diabetic ketoacidosis within 2 weeks of screening. Pregnancy or lactation. Recent (within 2 weeks of screening), ongoing, chronic or recurrent infectious disease. Active infection with hepatitis B or C, Epstein-Barr virus, cytomegalovirus, or HIV. Tuberculosis infection. Other protocol-defined inclusion/exclusion criteria may apply